Skip to main content

Table 2 Prior anti-migraine preventive therapies of patients (N = 70) in the study, showing pharmacological classes and corresponding reason for failure

From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

  Patients No meaningful improvement Adverse events Treatment discontinuationa
Tricyclic antidepressants 65 (93) 55 (85) 10 (15) 48 (68)
Beta-blockers 63 (90) 56 (88) 7 (12) 48 (68)
Calcium channel blockers 28 (40) 22 (78) 6 (12) 25 (36)
Topiramate 62 (88) 47 (76) 15 (24) 50 (71)
Valproate 15 (21) 9 (60) 6 (40) 13 (18)
OnabotulinumtoxinA 54 (77) 54 (100) 49 (70)
  1. Values are no. (%)
  2. a Due to no meaningful improvement or adverse event
\